Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
European Journal of Gastroenterology & Hepatology|July 8, 2022
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Scientific Reports|May 19, 2022
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patientsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Cancer Medicine|January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular CarcinomaAtsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Alimentary Pharmacology & Therapeutics|May 8, 2024
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trialToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCCTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Pageof 12